4th European CAR T-cell Meeting

The European Hematology Association (EHA) and the EBMT are excited to announce the 4th edition of the jointly organized European CAR T-cell Meeting. This meeting will be fully virtual. Read the welcome message from the chairs here

Dates: February 10-12, 2022
Chairs: Michael Hudecek & Ibrahim Yakoub-Agha
Format: Virtual

Registration is open for this meeting. Register here

The meeting will cover a broad range of topics including deep science and translational, clinical and commercial development in the field of CAR T. The program will bring you all the latest in CAR T and will even bring in the first ever reported clinical data.

Join the meeting to be able to hear the latest developments and to have the chance to discuss this important topic with both experts and your peers.

EHA Topics-in-Focus Immunotherapy

Topics in Focus Immunotherapy 01This meeting is part of the EHA Topics-in-Focus (TIF) program on Immunotherapy, aimed at raising awareness, providing education, furthering research, and building a network of experts to improve patient care. Further information, including a link to the brand-new website dedicated to Immunotherapy, please see our website.

Format

Due to the ongoing pandemic and varying travel restrictions this meeting has been converted from hybrid to fully virtual. All sessions are livestreamed and can be accessed by registered delegates on the virtual platform.

Target audience

The target audience is hematologists, oncologists, physicians, nurses, data managers, supply chain managers and patient organization representatives.

Program

The program will cover various CAR T-Cell related topics and will include key note lectures, interactive debate sessions and more. 

To view the program and latest updates, see the meeting program page

Scientific Program Committee

The Scientific Program Committee (SPC) have created the program and helped to select speakers. The members are:

  • Anna Sureda (Spain)
  • Christian Chabannon (France)
  • Francis Ayuk (Germany)
  • Michelle Kenyon (United Kingdom)
  • Erik Aerts (Switzerland)
  • Hermann Einsele (Germany)
  • Maria Themeli (The Netherlands)
  • Claire Roddie (United Kingdom)
  • Natacha Bolaños (Spain)
  • Guy Bouguet (france)

Abstract submission

Abstract submission is an important part of this meeting. As a participant, you will have the opportunity to submit an abstract for this meeting, and (if accepted) have the possibility to discuss it with the international faculty and your peers.

Introduced last year, we are excited to announce 2nd Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2022. Submitters can apply for this award and the Scientific Program Committee will select 3 winners. Winners will receive €10 000 and the opportunity to present their work on Day 1.

Late breaking abstract submission is open from January 3 to 10, 2022 to allow the latest data to be submitted and included in the exciting meeting program. Click here for more information.

Registration

Registration is open and it is possible to register individuals and groups for reduced rates until January 9. For more information and to register, click here.

Sponsorship


There are various opportunities to support this educational course. For more information, please send an email to sponsorship@ehaweb.org or fundraising@ebmt.org to indicate your interest.

This meeting is supported by:

Supreme Level Partner 

bms logo 300 rgb pos

jsn ta onc jj color rgb

 

Meeting Contributor

Logo MiltenyiBiomedicine RGB

Logo MiltenyiBiotec RGB

  EBAH accredited stamp DEF2

EBAH CME accreditation

This meeting is accredited by the European Board for Accreditation in Hematology (EBAH) CME. EBAH CME is the best way for hematologists to master the latest developments within the specialty of hematology. Staying abreast of these scientific developments and keeping in touch with the up-to-date views on clinical policy will enable you to raise your professional level, ultimately resulting in the best treatment for your patients.